Clinical correlates and prognostic significance of neuron specific enolase (NSE) in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Serum neuron-specific enolase - a marker for disease extent and response to therapy of small-cell lung cancerSource: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Prognostic significance of S-100 immmunostaining in non-small cell lung cancer (NSCLC) Source: Annual Congress 2004 - Prognostic factors Year: 2004
Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma Source: Eur Respir J 2007; 30: Suppl. 51, 290s Year: 2007
The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Prognostic significance of Nestin in resected non-small cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Clinical and prognostic significance of autoantibodies against recoverin in non small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 394s Year: 2003
Serum napsin A as a tumor marker for primary lung adenocarcinoma Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Neuroendocrine differentiation in non-small cell lung cancer. A biochemical, immunohistological and ultrastructural evaluation of Chromogranin A Source: Eur Respir J 2006; 28: Suppl. 50, 783s Year: 2006
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Expression of immunohistochemical markers chromogranin A, Ki-67, CD99, EGFR in resected pulmonary neuroendocrine tumors Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
The predictive value of neuroendocrine markers for response to chemotherapy and survival in patients with non-small cell lung Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012